A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS

Protocol: 
AAAR5625
Phase: 
I

A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS

The purpose of this study is to find out if the study treatment called
RO7198457 (PCV) can be safely given to patients with cancer. PCV is a
personalized cancer vaccine. Participants will either received PCV alone or in
combination with atezolizumab.

Are you Eligible? (Inclusion Criteria)

1. Participants must have confirmed cancer. Participants must have had
treatment for their disease before or have a disease that does not have
standard therapy.

2. Participants must be in good physical shape. This means that participants
must be able to walk, care for themselves, and do light physical activities
such as light housework or office work.

3. This study is for participants age 18 or older

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States